期刊
CLINICAL CANCER RESEARCH
卷 29, 期 14, 页码 2570-2572出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-23-0737
关键词
-
类别
A new designing strategy has discovered a bispecific therapeutic antibody co-targeting EPHA2 and EGFR, which effectively inhibits tumor cell growth in various preclinical cancer models. This antibody provides new tools to impair acquired resistance to EGFR-directed therapies or co-target EPHA2 and EGFR in human tumors.
Therapeutic antibodies selectively targeting EPHA2 with or without co-targeting another receptor tyrosine kinase have been limited to date. By integrating state-of-art proteogenomic, ex vivo models, and short hairpin RNA screening approaches, a new designing strategy has now discovered a bispecific therapeutic antibody co-targeting EPHA2 and EGFR - which effectively inhibits tumor cell growth in various preclinical cancer models. This new antibody provides new tools to impair the acquired resistance to EGFRdirected therapies or co-target EPHA2 and EGFR in human tumor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据